Day One Biopharmaceuticals, Inc.
NASDAQ:DAWN
13.79 (USD) • At close September 18, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 8.192 | 0 | 0.56 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.707 | 0.116 | 0.28 | 0.099 | 0.092 | 0.089 | 0.18 | 0.165 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 7.485 | -0.116 | 0.28 | -0.099 | -0.092 | -0.089 | -0.18 | -0.165 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0.914 | 0 | 0.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 92.106 | 40.21 | 37.348 | 33.163 | 32.182 | 27.828 | 26.02 | 22.035 | 22.56 | 15.003 | 43.584 | 9.849 | 9.914 | 12.632 | 4.165 | 2.537 | 1.437 | 0.961 |
| General & Administrative Expenses
| 30.186 | 26.557 | 22.169 | 18.275 | 17.072 | 18.027 | 16.723 | 17.664 | 14.159 | 12.745 | 29.159 | 9.392 | 5.525 | 3.454 | 1.979 | 1.024 | 0.872 | 0.808 |
| Selling & Marketing Expenses
| 0 | -0.116 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 30.186 | 26.441 | 22.169 | 18.275 | 17.072 | 18.027 | 16.723 | 17.664 | 14.159 | 12.745 | 29.159 | 9.392 | 5.525 | 3.454 | 1.979 | 1.024 | 0.872 | 0.808 |
| Other Expenses
| 107.99 | -0.01 | -0.018 | -0.003 | -0.015 | -0.004 | -0.026 | 0.009 | 0 | -0.001 | 0.014 | 0.007 | -0.027 | -0.008 | -0.026 | -0.001 | -0.09 | -0.002 |
| Operating Expenses
| 122.292 | 66.651 | 59.517 | 51.438 | 49.254 | 45.855 | 42.743 | 39.699 | 36.719 | 27.748 | 72.743 | 19.241 | 15.439 | 16.086 | 6.144 | 3.561 | 2.309 | 1.769 |
| Operating Income
| -114.807 | -66.767 | -59.517 | -51.438 | -49.254 | -45.855 | -42.743 | -39.699 | -36.719 | -27.748 | -121.931 | -19.241 | -15.439 | -16.086 | -6.144 | -3.561 | -2.309 | -1.769 |
| Operating Income Ratio
| -14.015 | 0 | -106.28 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 111.952 | 4.355 | 5.006 | 5.288 | 3.391 | 3.462 | 2.634 | 1.904 | 0.189 | 0.001 | 2.106 | 0.001 | -0.034 | -0.008 | -29.448 | -0.272 | -0.09 | -0.22 |
| Income Before Tax
| -2.855 | -62.412 | -54.511 | -46.15 | -45.863 | -42.393 | -40.109 | -37.795 | -36.53 | -27.747 | -119.825 | -19.24 | -15.473 | -16.101 | -35.6 | -3.842 | -2.409 | -1.992 |
| Income Before Tax Ratio
| -0.349 | 0 | -97.341 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 1.552 | 0.073 | 10.522 | -0.099 | -3.406 | -7.017 | -5.294 | -3.799 | -0.189 | -0.003 | 0.004 | 0.007 | -0.027 | -0.92 | -1.241 | -1.01 | -0.639 | -0.456 |
| Net Income
| -4.407 | -62.412 | -54.511 | -46.15 | -45.863 | -35.376 | -34.815 | -33.996 | -36.53 | -27.744 | -119.829 | -19.24 | -14.282 | -15.182 | -34.377 | -2.824 | -1.76 | -1.535 |
| Net Income Ratio
| -0.538 | 0 | -97.341 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.051 | -0.72 | -0.62 | -0.54 | -0.61 | -0.49 | -0.47 | -0.48 | -0.6 | -0.48 | -0.38 | -0.33 | -5.04 | -0.25 | -0.82 | -0.067 | -0.042 | -0.037 |
| EPS Diluted
| -0.051 | -0.72 | -0.62 | -0.54 | -0.61 | -0.49 | -0.47 | -0.48 | -0.6 | -0.48 | -0.38 | -0.33 | -5.04 | -0.25 | -0.82 | -0.067 | -0.042 | -0.037 |
| EBITDA
| -114.399 | -66.651 | -64.438 | -51.438 | -52.568 | -49.321 | -42.563 | -39.534 | -36.775 | -27.695 | -121.926 | -19.184 | -14.226 | -16.045 | -6.121 | -3.516 | -2.263 | -1.757 |
| EBITDA Ratio
| -13.965 | 0 | -115.068 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |